部份中文阿立哌唑处方资料（仅供参考）
商品名：ABILIFY
英文名：Aripiprazole Hydrate
中文名：阿立哌唑缓释型注射用混悬剂
生产商：大冢制药
エビリファイ持続性水懸筋注用300mgシリンジ/エビリファイ持続性水懸筋注用400mgシリンジ
药用类别名称
持续抗精神病药
批准日期：2015年5月
商標名
ABILIFY prolonged release aqueous suspension for IM injection
一般名：
アリピプラゾール水和物［Aripiprazole Hydrate （JAN）］
化学名：
7-{4-［4-（2,3-Dichlorophenyl）piperazin-1-yl］butoxy}-3,4-dihydroquinolin-2（1H）-one monohydrate
構造式：
分子式：
C23H27Cl2N3O2・H2O
分子量：
466.40
性　状：
它是一个白色的水晶。 四氢呋喃, 醋酸 (100), 易溶于苯醇, 微溶于二甲基亚硫酸, 几乎不溶于乙醇 (99.5), 很溶于甲醇, 难以溶于水。
批准条件
制定药品风险管理计划并加以实施。
药用药理学
1. 药理作用
(1) 受体亲和力
体外受体结合试验, 重组人多巴胺D216, 人多巴胺d3, 人血清素5-ht1a17), 并显示了人类血清素5-HT2A 受体的高亲和力5-ht2a受体, 人多巴胺d4, 人血清素5-HT2C 显示了对人血清素5-HT7、大鼠大脑皮层α-肾上腺素和人组胺 H1受体的适度亲和力。 牛纹状体M1对大鼠心肌肌钙素 M2 和豚鼠伊莱尔肌钙素m3受体的亲和力较低。
(2) 多巴胺D2受体部分激动剂作用
作为多巴胺D2受体体外试验的部分激动剂。体外和体内试验, 在一种状态下, 多巴胺驱动的神经传输增强作为对抗多巴胺D2受体, 在多巴胺引起的神经传递减少的状态下, 它被作为多巴胺D2受体的激动剂。
(3) 多巴胺D3受体部分激动剂作用
在体外试验中, 它被用作多巴胺D3受体的部分激动剂。
(4) 血清素5-HT1A受体部分激动剂作用
在体外试验中, 它被用作血清素5-HT1A受体的部分激动剂。 降低小鼠脑中5-羟基丁醇醋酸的血清素代谢产物, 抑制了大鼠战争遗留爆炸物线核的血清素神经元点火。
(5) 血清素5-HT2A受体拮抗剂活性
血清素5-HT2A受体激动剂引起的抑制行为改变。此外, 体外试验, 以抑制大鼠P11细胞内Ca2+浓度的增加由血清素。
(6) 改善对与精神分裂症症状相关的动物模型的影响
抑制大鼠病情回避反应被认为是积极症状的指标, 抑制大鼠冲突反应被认为是焦虑症状的指标。
(7) 加泰罗尼亚语引起的作用
对APO吗啡诱导小鼠和大鼠抗常规作用的Eed50值比大于氯丙嗪和氟哌啶。
(8) 对调节血催乳素浓度的前叶多巴胺d2受体的影响
体外试验可作为大鼠垂体前叶多巴胺D2受体的局部激动剂。
2. 作用机制
阿立哌唑, 多巴胺D2受体部分激动剂作用, 多巴胺D3受体部分激动剂作用, 具有血清素5-ht1a受体部分激动剂作用和血清素5-HT2A受体拮抗剂作用的药物。虽然一个明确的机制尚不清楚, 但这些药理作用被认为有助于临床的有用性。
适应症
●精神分裂症
用法与用量
通常情况下, 成人在4周内在臀部肌肉组织或三角肌肉中服用一次400毫克1次阿立哌唑。 此外, 要减肥到300毫克一次, 这取决于症状和耐受性。
包装
悬浮肌肉300毫克注射器: 1个注射器
水悬浮液, 用于分配400毫克注射器: 1注射器
制造和销售来源
大冢制药
注：以上中文处方资料不够完整，使用者以原处方资料为准。
完整说明附件：http://www.info.pmda.go.jp/go/pack/1179410G1028_1_06/ 
阿立哌唑（Abilify）是一种新型的非典型抗精神病药物，对多巴胺D2受体具有部分激动作用，通过激动D2受体，提高额叶区不足的多巴胺功能，改善阴性症状，并且减低中脑-边缘系统通路过高的多巴胺功能以改善阳性症状。
ABILIFY prolonged release aqueous suspension for IM injection 400 mg（エビリファイ持続性水懸筋注用400mg）
Brand name : ABILIFY prolonged release aqueous suspension for IM injection 400 mg
　Active ingredient: Aripiprazole hydrate
　Dosage form: injection
　Print on wrapping:
Effects of this medicine
This medicine acts on receptors for neurotransmitters such as dopamine in the brain, to suppress symptoms such as hallucinations and delusions, stabilize unstable mental status, and improve symptoms such as lack of motivation and loss of interest.
It is usually used in the treatment of schizophrenia.
Before using this medicine, be sure to tell your doctor and pharmacist
If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have diabetes or if you or your family has a history of diabetes.
If you have: hepatic disorder, cardiovascular disease or hypotension, convulsive disease such as epilepsy or a history thereof, suicidal attempt or suicidal ideation.
If you are pregnant or breastfeeding.
If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
In general, this medicine is administered intramuscularly into the gluteal muscle once every 4 weeks.
This medicine may be administered over a long period according to your response to the treatment.
Ask your doctor regarding the frequency of your injections.
Precautions while taking this medicine
This medicine may cause sleepiness; decreased attentiveness, concentration and reflex movements. Avoid operating dangerous machinery such as driving a car.
Alcohol may intensify the therapeutic effects of the medicine. Be careful when drinking alcohol.
Because the effect of this medicine lasts one month after administration, you need to beware of its adverse effects or the use of other medicines until this medicine has been completely eliminated from your body. If you visit other medical institutions, tell your doctor or pharmacist that you are using this medicine.
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include injection site pain, injection site erythema, injection site induration, injection site swelling, weight increase, and akathisia (restlessness). If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, see your doctor immediately.
dry mouth, excessive intake of water, increased urine output [diabetic ketoacidosis, diabetic coma]
being silent without moving, muscle stiffness, sudden fever [neuroleptic malignant syndrome]
moving the tongue, putting the tongue out and pulling it back in, continual movement of the mouth appearing to chew something [tardive dyskinesia]
nausea, vomiting, constipation, intense abdominal pain [paralytic ileus]
weakness, muscle pain, reddish brown urine [rhabdomyolysis]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Otsuka Pharmaceutical Co., Ltd.Injection
Published: 5/2015
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.